Hepatic CD36 up-regulation has been significantly associated with insulin resistance and steatosis in NAFLD patients (Koonen et al, 2007; Heeboll et al, 2017). This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.